Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.

doi:10.1158/1078-0432.CCR-17-0782

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2017

Poulsen Thomas Tuxen, Grandal Michael Monrad, Skartved Niels Jørgen Østergaard, Hald Rikke, Alifrangis Lene, Koefoed Klaus, Lindsted Trine, Fröhlich Camilla, Pollmann Sofie Ellebæk, Eriksen Karsten Wessel, Dahlman Anna, Jacobsen Helle Jane, Bouquin Thomas, Pedersen Mikkel Wandahl, Horak Ivan David, Lantto Johan, Kragh Michael

Abstract excerpt

Purpose: Activation of the receptor tyrosine kinase MET is associated with poor clinical outcome in certain cancers. To target MET more effectively, we developed an antagonistic antibody mixture, Sym015, consisting of two humanized mAbs directed against nonoverlapping epitopes of MET.Experimental Design/Results: We screened a large panel of well-annotated human cancer cell lines and identified a subset with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antibody-Dependent Cell Cytotoxicity

Share to Epitopes

Share to Gene Amplification

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 28679766
DOI: 10.1158/1078-0432.CCR-17-0782

Genes

MET
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.PMID 28679766Read ↗

Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.Semantic proximity Read ↗

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.Semantic proximity Read ↗

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.Semantic proximity Read ↗

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.Semantic proximity Read ↗

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.Semantic proximity Read ↗

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of osimertinib, against NSCLC cells with acquired resistance to osimertinib due to MET amplificationSemantic proximity Read ↗

Targeting MET in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.Semantic proximity Read ↗

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.